[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553459":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":24,"responsibleParty":39,"collaborators":24,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":24,"eligibilityCriteria":47,"healthyVolunteers":44,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":24,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":24,"overallStatus":61,"whyStopped":24,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":24},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Aspirin combined with clopidogrel","ACTIVE_COMPARATOR","Participants in this group shall take Aspirin (100 mg\u002Fday) + clopidogrel (75 mg\u002Fday) for at least 5 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment",[13],"Drug: Aspirin combined with clopidogrel",{"label":15,"type":16,"description":17,"interventionNames":18},"Aspirin combined with half-dose ticagrelor","EXPERIMENTAL","Participants in this group shall take Aspirin (100 mg\u002Fday) + half dose of ticagrelor (45 mg, 12 hours\u002Ftime), at least for 3 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment.",[19],"Drug: Aspirin combined with half-dose ticagrelor",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":22,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Participants in this group shall take Aspirin (100 mg\u002Fday) + half dose of ticagrelor (45 mg, 12 hours\u002Ftime), at least for 3 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment",[15],[29],{"name":30,"affiliation":31,"role":32},"Shijie Na, Doctor","The Affiliated Nanjing Drum Tower Hospital of Nanjing university","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},"Zong Zhuang, Doctor","CONTACT","+86 15850560410","zhuangzong@126.com",{"type":32,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Shijie Na","Deputy chief physician of Neurosurgery, Principal Investigator","100553459","phase-4-comparison-of-the-antiplatelet-efficacy-of-aspirin-combined-with-clopidogrel-and-aspirin-combined-with-half-dose-ticagrelor-in-patients-with-unruptured-intracranial-aneurysms-with-normal-cyp2c19-metabolizer-phenotype-100553459",false,"NCT06486363","Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype","Inclusion Criteria:\n\n1. Patients with unruptured intracranial aneurysms who are scheduled for stent-assisted embolization;\n2. mRS score less than or equal to 2 on admission;\n3. Normal CYP2C19 metabolizer genotype;\n4. Age 20 or above, 70 or below, regardless of gender;\n5. The subject or the entrusted family member voluntarily signed the informed consent for this trial\n\nExclusion Criteria:\n\n1. Use of drugs that affect coagulation function or significant abnormalities in platelet\u002Fcoagulation function before admission;\n2. Previous history of cardiovascular and cerebrovascular disease;\n3. Complications of major organ dysfunction, chronic inflammatory diseases or malignant tumors at admission;\n4. Known allergy or contraindication to heparin, aspirin, clopidogrel, or ticagrelor;\n5. Patients with any severe or active pathological bleeding;\n6. Pregnant and lactating female;\n7. Those deemed unsuitable to participate in this trial by the responsible physician","ALL","20 Years","70 Years",{"count":52,"type":53},196,"ESTIMATED","INTERVENTIONAL",[56],"PHASE4","The goal of this clinical trial is to compare the antiplatelet efficacy of aspirin combined with clopidogrel and aspirin combined with half-dose ticagrelor in in patients with unruptured intracranial aneurysms with normal CYP2C19 metabolizer phenotype. The main questions it aims to answer are:\n\nIf aspirin combined with half-dose ticagrelor is comparable to or better than aspirin combined with clopidogrel? What medical problems do participants have when taking aspirin combined with half-dose ticagrelor? Researchers will compare aspirin combined with half-dose ticagrelor to aspirin combined with clopidogrel to see if aspirin combined with half-dose ticagrelor works to treat patients with unruptured intracranial aneurysms received endovascular treatment.\n\nParticipants will:\n\nTake aspirin combined with half-dose ticagrelor or aspirin combined with clopidogrel every day for 6 months Visit the clinic 1 month and 6 months for checkups and tests",[59,60],"Intracranial Aneurysms","Antiplatelet Drugs","NOT_YET_RECRUITING","2024-07-26",{"date":64,"type":65},"2024-07-29","ACTUAL",{"date":67,"type":53},"2024-08-01",{"date":69,"type":53},"2027-07-31",{"name":5,"class":6}]